Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,575.83
(
-0.74%
)
US TECH 100
23,615.20
(
-0.76%
)
Dow Jones
45,802.76
(
-0.91%
)
Brent Oil
105.66
(
-0.87%
)
Bitcoin
69,705.47
(
-2.16%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 116998

Saturday, 05/21/2011 5:40:58 PM

Saturday, May 21, 2011 5:40:58 PM

Post# of 257259
CHMP approves BMY’s Yervoy for second-line melanoma:

http://www.reuters.com/article/2011/05/20/bristol-melanoma-europe-idUSLDE74J13T20110520

The European Medicines Agency said its expert committee on new drugs had backed the drug as a treatment for patients with advanced melanoma who had received prior therapy.

In other words, the EMA is giving BMY what they asked for rather than giving them more than they asked for, as the FDA did two months ago (#msg-61357010).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now